Saba Capital Management’s DA32 Life Science Tech Acquisition Corp. Class A Common Stock DALS Stock Holding History

Saba Capital Management’s Portfolio DALS Stock Details DALS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,240,593	Closed	-$12.7M	–	647
2023 Q2	$12.7M	Sell	1,240,593 -17,684	-1%	-$180K	0.33%	77
2023 Q1	$12.7M	Hold	1,258,277	–	–	0.24%	134
2022 Q4	$12.6M	Hold	1,258,277	–	–	0.17%	198
2022 Q3	$12.2M	Hold	1,258,277	–	–	0.14%	267
2022 Q2	$12.2M	Buy	1,258,277 +138,000	+12%	+$1.34M	0.14%	246
2022 Q1	$10.9M	Buy	+1,120,277	New	+$10.8M	0.16%	209

Saba Capital Management's DALS Position: Q3 2023 in Review

Saba Capital Management sold out of DA32 Life Science Tech Acquisition Corp. Class A Common Stock (DALS) in Q3 2023, closing a stake of 1,240,593 shares — an estimated $12.7M sold.

Saba Capital Management first reported a position in DALS in Q1 2022 and held it in 6 quarters. The position peaked at $12.7M in Q1 2023. 0 funds tracked by Wall St. Rank hold DALS as of Q3 2023.

Saba Capital Management reported no remaining DA32 Life Science Tech Acquisition Corp. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Saba Capital Management sold 1,240,593 DA32 Life Science Tech Acquisition Corp. Class A Common Stock shares in Q3 2023, an estimated $12.7M.
Saba Capital Management first reported a position in DA32 Life Science Tech Acquisition Corp. Class A Common Stock in Q1 2022 and held it in 6 quarters.
Saba Capital Management's DA32 Life Science Tech Acquisition Corp. Class A Common Stock position peaked at $12.7M in Q1 2023.
0 funds tracked by Wall St. Rank held DA32 Life Science Tech Acquisition Corp. Class A Common Stock as of Q3 2023.

Based on Saba Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.